Appendices to Section 6.3

Cardiovascular Disease

6.3.1   

Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk pateints. BMJ. 2002;324:71-86. [pdf 409KB]

6.3.2  

(1) Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-258.  [pdf 119KB]  

(2) PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.  [pdf 116KB] 

Reprinted with permission from Elsevier. (1. Lancet 2000;355:253-258 and 2. Lancet. 2001;358:1033-1041). The Lancet Homepage is at http://www.thelancet.com

6.3.3 

EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet. 2001;357:996-1001. [pdf 104KB]

Reprinted with permission from Elsevier. (Lancet 2001;357:996-1001).

6.3.4  

Patents relevant to the risk pill [word 101KB]

6.3.5

Secondary prevention of noncommunicable diseases [pdf 467KB]

6.3.6 

Prevention of Recurrent Heart Attacks and Strokes in Low-and Midlle-Income Populations [pdf 23KB]

6.3.7  

Crude estimates of effects on cardiovascular events of different levels of use of proven secondary preventive treatments [word 28KB]

6.3.8 

Concept paper on the development of a committee for medicinal products for human use (CHMP) -- Note for guidance on the need for regulatory guidance in the evaluation of medicinal products for the secondary cardiovascular prevention [pdf 135KB]